Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline

R. Sanmartín, J. Tor, A. Sanvisens, Jj López, A. Jou, R. Muga, I. Ojanguren, E. Barluenga, S. Videla, R. Planas, B. Clotet, C. Tural

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Abstract

Objectives: The aim of the study was to assess the progression of liver fibrosis in HIV/hepatitis C virus (HCV)-coinfected patients with no or mild-to-moderate fibrosis (stages F0-F2). Methods: Liver fibrosis was reassessed by transient elastometry (TE) between January 2009 and November 2011 in HIV/HCV-coinfected patients with stage F0-F2 fibrosis in a liver biopsy performed between January 1997 and December 2007. Patients with liver stiffness at the end of follow-up <7.1kPa were defined as nonprogressors, and those with values ≥9.5kPa or who died from liver disease were defined as progressors. Cirrhosis was defined as a cut-off of 14.6kPa. The follow-up period was the time between liver biopsy and TE. Cox regression models adjusted for age, gender and liver fibrosis stage at baseline were applied. Results: The median follow-up time was 7.8 years [interquartile range (IQR) 5.5-10 years]. The study population comprised 162 patients [115 (71%) nonprogressors and 47 (29%) progressors; 19 patients (11.7%) had cirrhosis]. The median time from the diagnosis of HCV infection to the end of follow-up was 20 years (IQR 16.3-23.1 years). Three progressors died from liver disease (1.8%). The variables associated with a lower risk of progression were age ≤38 years (hazard ratio (HR) 0.32; 95% confidence interval (CI) 0.16-0.62; P=0.001], having received interferon (HR 2.18; 95% CI 1.14-4.15; P=0.017), being hepatitis B virus surface antigen (HBsAg) negative (HR 0.20; 95% CI 0.04-0.92; P=0.039), and baseline F0-F1 (HR 0.43; 95% CI 0.28-0.86; P=0.017). Conclusions: A high proportion of patients with stage F0-F2 fibrosis progress to advanced liver fibrosis. Advanced liver fibrosis must be included in the list of diseases associated with aging. Our results support the recommendation to offer HCV antiviral therapy to HIV/HCV-coinfected patients at early stages of liver fibrosis. © 2013 British HIV Association.
Original languageEnglish
Pages (from-to)203-212
JournalHIV Medicine
Volume15
Issue number4
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • HIV/HCV coinfection
  • Liver biopsy
  • Liver fibrosis
  • Transient elastometry

Fingerprint

Dive into the research topics of 'Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline'. Together they form a unique fingerprint.

Cite this